Mutation of KRAS tops other genes that were possibly associated with improved immunotherapy responses, followed by p53. It has been documented that KRAS mutations can enhance PD-L1 expression, promote T cell infiltration and enhance tumor immunogenicity (42). The gene discussed is TP53; the disease is neoplasm.